Arizona Tribune - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

NYSE - LSE

CMSC	0.18%	21.99	$
NGG	3.22%	82.85	$
VOD	1.06%	13.15	$
GSK	4.4%	53.66	$
CMSD	-0.14%	22.15	$
RELX	1.72%	31.93	$
BCE	1.87%	21.42	$
RYCEF	2.74%	19.68	$
RIO	1.13%	94.42	$
RBGPF	3.73%	68.15	$
JRI	0.46%	13	$
BCC	0.59%	75.93	$
AZN	5.79%	195.15	$
BTI	1.96%	61.77	$
BP	3.34%	37.4	$

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

TECHNOLOGY 27.02.2025

FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. 

Text size:

Details for the presentation are as follows:  

Abstract Number:  123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter:  Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time:  Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT

For more information, please visit the conference website here. 

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

S.Jackson--AT

Featured

Taiwanese film hunters rescue ageing reels from bygone era

New species of ghost shark may have been found in Costa Rica

New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group